US DoD awards another £2m for Epistem biohazard project
21st Mar 2016 15:37
(ShareCast News) - Epistem Holdings was gearing up for the next stage of its development programme with the US Department of Defense on Monday, having been awarded funding to proceed. The AIM-traded company received $2.4m (£1.7m) for the first phase of the $7.8m programme in August last year, to dev
Read moreHangar 8 CEO makes first sale to meet demand for stock
3rd Dec 2013 15:59
Hangar 8, a privately-owned passenger jet aircraft owner, announced that Dustin Dryden, its Chief Executive Office, made his first ever sale of company stock with the disposal of 750,000 shares to meet institutional demand. Dryden sold the shares at 205p each for a total of £1.54m and reduced his
Read moreEpiStem loses distribution contract for TB test
9th Sep 2013 08:00
AIM-listed biotech firm EpiStem has maintained its full-year guidance for the period just gone but admitted that talks over a key supply and distribution agreement for its TB test have fallen through. The company was in discussions with medical technology company Becton Dickinson (BD) to expand the
Read moreEpistem to raise 4.3m pounds via placing
7th Dec 2012 15:22
Epistem, a biotechnology and personalised medicine company is to raise 4.3m pounds before expenses through a placing of approximately 793.4m shares at 545p a share. The new ordinary shares, which represent 8.9% of Epistem's issued share capital have been conditionally placed with existing and new i
Read moreInvestec invests in Epistem
24th Oct 2012 15:32
Investec Asset Management has taken a 7.05 per cent stake in Epistem, a biotech firm working in the area of personalised medicine. Over the past three months the loss-making AIM-listed company, Epistem, has shot up approximately 50%. Earlier this month it reported steady full-year results, while d
Read moreEpistem delivers steady performance
16th Oct 2012 08:07
Biotechnology firm Epistem has delivered steady full-year results, while also accelerating investment in a number of its core development programmes. Total sales of £5.6m (2011: £5.8m) were driven by a solid performance by Contract Research Services and strong growth in its Personalised Medicine d
Read moreEpistem secures contract for TB test
6th Aug 2012 08:59
EpiStem, the pre-clinical drugs test firm, has reported that full year trading has been broadly in-line with market forecasts. The firm also said it has reached agreement with US firm Becton Dickinson for the supply and distribution of its Mycobacterium tuberculosis (TB) test on a global basis usin
Read moreSmall caps round-up: Epistem, Stadium Group, Trading Emissions
5th Jul 2012 10:42
Biotechnology firm Epistem Hldings said it had received the go-ahead to sells its new tuberculosis product in EEA member state markets. The firm said its Genedrive units provided a major advance in next generation molecular diagnostic testing. Epistem is now preparing regulatory submissions for Indi
Read moreBig things expected of EpiStem's Genedrive device
11th Oct 2011 08:44
Epistem, the biotechnology company specialising in diagnostic aids for the treatment of cancer and gastrointestinal diseases, continued on its steady growth path last year. Revenue in the year to June 30th edged up to £5.75m from £5.74m the year before, while profit on ordinary activities before ta
Read moreEpistem sees solid growth
29th Mar 2011 13:23
Adult stem cell specialist Epistem scraped into profit in the first half of its financial year. The company, which made its maiden full year profit last year, saw profit before tax in the six months to the end of December rise to £0.1m from £5,000 in the corresponding period of 2009. Revenue rose
Read moreMaiden pre-tax profit for Epistem
5th Oct 2010 13:28
UK biotech company, Epistem, celebrates the full year results with a maiden pre-tax profit since becoming an AIM-listed company in 2007. The group has swung to a pre-tax profit of £0.35m, from last year's loss of £0.67m. Revenues rose 45% to £5.7m, from £4.0m previously, as sales rose across all di
Read moreSmall caps: Titon, Utd Drug, Vernalis...
29th Jul 2010 14:16
Blinds specialist Titon's revenues for the 3 months to June were 19% higher than the corresponding period last year, with UK sales 15% higher and the rest of the world 37% higher. Growth in the UK came from higher sales of mechanical ventilation systems. There were also increased sales volumes in
Read moreEpistem FY Trading In line With Market Views, Sees Pretax Profit Up
29th Jul 2010 07:38
LONDON (Dow Jones)--Epistem Holdings PLC (EHP.LN), a biotechnology company, said Thursday that trading over the year was in line with market forecasts and the company expects to report growth in year on year after tax profit. -Shares closed Wednesday at 360 pence, valuing the company at GBP28.36
Read moreEpiStem breaks even as revenue soars
9th Mar 2010 12:03
The Novel Therapies division is threatening to steal the show at epithelial stem cells specialist Epistem, as the benefits of its transformational deal with Swiss pharmaceutical giant Novartis kicks in. The UK biotechnology company saw revenue soar 90% in 2009 almost entirely as a result of the co
Read moreSmall caps round-up: Nautical Petroleum, ThirdForce, Allied Gold...
9th Nov 2009 11:43
Oil group Nautical Petroleum reported 'significant progress' in its asset portfolio in the year to June 30 and said it expects its assets to rise in value once they move into the execution stage. Pre-tax losses for the year totalled £6.63m, compared with £4.52m the previous year. Shares in e-learn
Read more